Global conformational earrangements in integrin extracellular domains in outside-in and inside-out signaling

Cell

Volumn 110, Issue 5, 2002, Pages 599-611

  Takagi, Junichi ^a   Petre, Benjamin M ^a   Walz, Thomas ^a   Springer, Timothy A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B BETA3 INTEGRIN; DISULFIDE; INTEGRIN; MANGANESE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; FIBRINOGEN RECEPTOR; LIGAND;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ELECTRON MICROSCOPY; LIGAND BINDING; MUTATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; PROTEIN BINDING; ULTRASTRUCTURE;

ANIMALIA;

HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; LIGANDS; MANGANESE; MICROSCOPY, ELECTRON; MODELS, MOLECULAR; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 0037031906     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(02)00935-2     Document Type: Article

References (45)

1. Bailey S. The CCP4 suite-programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:1994;760-763.
2. Bazzoni G., Hemler M.E. Are changes in integrin affinity and conformation overemphasized? Trends Biochem. Sci. 23:1998;30-34.
3. Bazzoni G., Ma L., Blue M.-L., Hemler M.E. Divalent cations and ligands induce conformational changes that are highly divergent among β1 integrins. J. Biol. Chem. 273:1998;6670-6678.
4. Bednar B., Cunningham M.E., McQueney P.A., Egbertson M.S., Askew B.C., Bednar R.A., Hartman G.D., Gould R.J. Flow cytometric measurement of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets. Cytometry. 28:1997;58-65.
5. Beglova N., Blacklow S.C., Takagi J., Springer T.A. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat. Struct. Biol. 9:2002;282-287.
6. Billheimer J.T., Dicker I.B., Wynn R., Bradley J.D., Cromley D.A., Godonis H.E., Grimminger L.C., He B., Kieras C.J., Pedicord D.L.et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 99:2002;1-7.
7. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
8. Coller B.S. Anti-GPIIb/IIIa drugs. current strategies and future directions Thromb. Haemost. 86:2001;427-443.
9. Conte L.L., Chothia C., Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285:1999;2177-2198.
10. Dechantsreiter M.A., Planker E., Matha B., Lohof E., Holzemann G., Jonczyk A., Goodman S.L., Kessler H. N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. J. Med. Chem. 42:1999;3033-3040.
11. Du X., Plow E.F., Frelinger A.L. III, O'Toole T.E., Loftus J.C., Ginsberg M.H. Ligands "activate" integrin αIIbβ3 (platelet GPIIb-IIIa). Cell. 65:1991;409-416.
12. 3. J. Biol. Chem. 268:1993;23087-23092.
13. Egbertson M.S., Cook J.J., Bednar B., Prugh J.D., Bednar R.A., Gaul S.L., Gould R.J., Hartman G.D., Homnick C.F., Holahan M.A.et al. Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. J. Med. Chem. 42:1999;2409-2421.
14. Falke J.J., Hazelbauer G.L. Transmembrane signaling in bacterial chemoreceptors. Trends Biochem. Sci. 26:2001;257-265.
15. Frank J., Radermacher M., Penczek P., Zhu J., Li Y., Ladjadj M., Leith A. Spider and web. processing and visualization of images in 3D electron microscopy and related fields J. Struct. Biol. 116:1996;190-199.
16. Frelinger A.L., Cohen I., Plow E.F., Smith M.A., Roberts J., Lam S.C.T., Ginsberg M.H. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. 265:1990;6346-6352.
17. Giancotti F.G., Ruoslahti E. Integrin signaling. Science. 285:1999;1028-1032.
18. Giblin P.A., Kelly T.A. Antagonists of β2 integrin-mediated cell adhesion. Annu. Rep. Med. Chem. 36:2001;181-190.
19. Hemler M.E. Integrin associated proteins. Curr. Opin. Cell Biol. 10:1998;578-585.
20. Huber W., Hurst J., Schlatter D., Barner R., Hübscher J., Kouns W.C., Steiner B. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. Eur. J. Biochem. 227:1995;647-656.
21. Hughes P.E., Pfaff M. Integrin affinity modulation. Trends Cell Biol. 8:1998;359-364.
22. Hughes P.E., Diaz-Gonzalez F., Leong L., Wu C., McDonald J.A., Shattil S.J., Ginsberg M.H. Breaking the integrin hinge. J. Biol. Chem. 271:1996;6571-6574.
23. Kouns W.C., Kirchhofer D., Hadvary P., Edenhofer A., Weller T., Pfenninger G., Baumgartner H.R., Jennings L.K., Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood. 80:1992;2539-2547.
24. Legler D.F., Wiedle G., Ross F.P., Imhof B.A. Superactivation of integrin αVβ3 by low antagonist concentrations. J. Cell Sci. 114:2001;1545-1553.
25. Liu S., Calderwood D.A., Ginsberg M.H. Integrin cytoplasmic domain-binding proteins. J. Cell Sci. 113:2000;3563-3571.
26. Lu C., Ferzly M., Takagi J., Springer T.A. Epitope mapping of antibodies to the C-terminal region of the integrin β2 subunit reveals regions that become exposed upon receptor activation. J. Immunol. 166:2001;5629-5637. a.
27. Lu C., Takagi J., Springer T.A. Association of the membrane-proximal regions of the α and β subunit cytoplasmic domains constrains an integrin in the inactive state. J. Biol. Chem. 276:2001;14642-14648. b.
28. Marvin J.S., Hellinga H.W. Manipulation of ligand binding affinity by exploitation of conformational coupling. Nat. Struct. Biol. 8:2001;795-798.
29. Nermut M.V., Green N.M., Eason P., Yamada S.S., Yamada K.M. Electron microscopy and structural model of human fibronectin receptor. EMBO J. 7:1988;4093-4099.
30. Pampori N., Hato T., Stupack D.G., Aidoudi S., Cheresh D.A., Nemerow G.R., Shattil S.J. Mechanisms and consequences of affinity modulation of integrin αVβ3 detected with a novel patch-engineered monovalent ligand. J. Biol. Chem. 274:1999;21609-21616.
31. Parise L.V., Helgerson S.L., Steiner B., Nannizzi L., Phillips D.R. Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb-IIIa. J. Biol. Chem. 262:1987;12597-12602.
32. Perutz M.F. Mechanisms of cooperativity and allosteric regulation in proteins. Q. Rev. Biophys. 22:1989;139-237.
33. Peter K., Schwarz M., Ylanne J., Kohler B., Moser M., Nordt T., Salbach P., Kubler W., Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood. 92:1998;3240-3249.
34. Remy I., Wilson I.A., Michnick S.W. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 283:1999;990-993.
35. Scarborough R.M., Gretler D.D. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers. novel parenteral and potential oral antithrombotic agents J. Med. Chem. 43:2000;3453-3473.
36. Schwartz M.A., Ginsberg M.H. Networks and crosstalk. integrin signalling spreads Nat. Cell Biol. 4:2002;E65-E68.
37. Shimaoka M., Takagi J., Springer T.A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 31:2002;485-516.
38. Smith J.W., Piotrowicz R.S., Mathis D. A mechanism for divalent cation regulation of β3-integrins. J. Biol. Chem. 269:1994;960-967.
39. Takagi J., Erickson H.P., Springer T.A. C-terminal opening mimics "inside-out" activation of integrin α5β1. Nat. Struct. Biol. 8:2001;412-416.
40. Tanford C. Physical Chemistry of Macromolecules. First Edition:1961;Wiley and Sons, Inc, New York.
41. 3 "inside-out" activation as regulated by its cytoplasmic face. Cell. 110:2002;587-597. this issue,
42. Xiong J.-P., Stehle T., Diefenbach B., Zhang R., Dunker R., Scott D.L., Joachimiak A., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3. Science. 294:2001;339-345.
43. Xiong J.P., Stehle T., Zhang R., Joachimiak A., Frech M., Goodman S.L., Arnaout M.A. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science. 295:2002;151-155.
44. Yan B., Smith J.W. Mechanism of integrin activation by disulfide bond reduction. Biochemistry. 40:2001;8861-8867.
45. Zang Q., Springer T.A. Amino acid residues in the PSI domain and cysteine-rich repeats of the integrin β2 subunit that restrain activation of the integrin αXβ2. J. Biol. Chem. 276:2001;6922-6929.